RIPRETINIB for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 93 adverse event reports in the FDA FAERS database where RIPRETINIB was used for Neoplasm malignant.
Most Reported Side Effects for RIPRETINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 582 | 13.1% | 17 | 86 |
| Alopecia | 517 | 11.7% | 7 | 66 |
| Extra dose administered | 357 | 8.1% | 32 | 65 |
| Death | 356 | 8.0% | 356 | 63 |
| Underdose | 345 | 7.8% | 19 | 67 |
| Nausea | 292 | 6.6% | 11 | 62 |
| Drug ineffective | 291 | 6.6% | 15 | 53 |
| Disease progression | 290 | 6.5% | 67 | 48 |
| Hospitalisation | 280 | 6.3% | 26 | 280 |
| Neoplasm progression | 263 | 5.9% | 20 | 49 |
| Constipation | 249 | 5.6% | 15 | 50 |
| Pain | 247 | 5.6% | 14 | 62 |
| Diarrhoea | 238 | 5.4% | 4 | 37 |
| Muscle spasms | 221 | 5.0% | 2 | 30 |
| Adverse event | 214 | 4.8% | 5 | 36 |
Other Indications for RIPRETINIB
Gastrointestinal stromal tumour (3,351)
Product used for unknown indication (757)
Malignant connective tissue neoplasm (139)
Soft tissue sarcoma (110)
Gastric cancer (28)
Malignant melanoma (20)
Metastases to liver (11)
Systemic mastocytosis (10)
Connective tissue neoplasm (8)
Neoplasm (7)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)